Clinical value of dysregulated miR-125b-5p in severe pneumonia children.

miR-125b-5p 失调在重症肺炎患儿中的临床价值

阅读:25
作者:Zhu Meiqin, Lu Ziyan, Liao Xingjuan, Liang Qin, Xu Chao, Luo Xinbing, Li Jun
BACKGROUND: Severe pneumonia is an important contributor to the high mortality of sick young children. The microRNA-125b-5p (miR-125b-5p), which is widely involved in various cancers, is closely related to a variety of lung diseases. However, its role in severe pneumonia children remains to be studied. OBJECTIVE: This study focused on the expression and clinical value of miR-125b-5p in severe pneumonia children. MATERIALS AND METHODS: The study subjects included 96 pneumonia children and 127 severe pneumonia children. These children were aged between 2-10 years. The expression level of serum miR-125b-5p was assessed by qRT-PCR. The receiver operator characteristic (ROC) curve was employed to identify severe pneumonia children from pneumonia individuals. Kaplan-Meier curve was plotted based on follow-up results and multivariate Cox regression analysis was applied to evaluate the contribution of miR-125b-5p to poor prognostic in severe pneumonia children. RESULTS: MiR-125b-5p was remarkedly reduced in severe pneumonia children compared to pneumonia individuals. The area under the curve (AUC) was 0.9267 and the sensitivity and specificity were 84.25% and 89.58%, respectively. The accumulative survival rate in low miR-125b-5p group showed a remarkable decrease compared to the high miR-125b-5p group (P = 0.033). Increased procalcitonin (PCT, HR: 2.631, 95% CI: 1.029-6.732, P = 0.043) and reduced miR-125b-5p (HR: 0.301, 95% CI: 0.110-0.826, P = 0.020) were found to be related to the poor prognosis in severe pneumonia children. CONCLUSION: The reduced miR-125b-5p was an underlying diagnostic indicator of severe pneumonia and was an independent risk factor of poor prognosis in severe pneumonia children.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。